Back to discover
Drug

Vardenafil

Approved · EMA
Late-stage development
Also known as Levitra, Staxyn, Vardenafilo, Vardenafil Hydrochloride+1 more

Levitra, Staxyn, Vardenafilo, Vardenafil Hydrochloride, Vardenafilum.

1
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Levitra (EMA)

Regulatory2003-03-06EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vardenafil
Aliases & brands
LevitraStaxynVardenafiloVardenafil HydrochlorideVardenafilum
RxNorm CUI
306674
ChEMBL ID
CHEMBL1520
UNII
UCE6F4125H
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2003-03-06
Latest approval
2003-03-06
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2003-03-06Approval
Approval: Levitra (EMA)
Indication: Treatment of erectile dysfunction in adult men. Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. InShow full indication

Treatment of erectile dysfunction in adult men. Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Levitra to be effective, sexual stimulation is required. Levitra is not indicated for use by women.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

24 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
24
registered trials across all phases
LATEST COMPLETION 2024
1
Active studies
1
Recruiting
16
Late-stage (III+)
17
Completed
6
Discontinued
PHASE DISTRIBUTIONn = 24
Early Phase 11Phase 12Phase 1 / 21Phase 24Phase 2 / 31Phase 33Phase 411Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.